Lentivirus News and Research

RSS

Lentivirus is a genus of slow viruses of the Retroviridae family, characterized by a long incubation period.

Study Reveals Diversity of DNA Transposons and Expands Genome Engineering Toolbox

In a study published in Cell, a research team led by Zhang Yong'e and WANG Haoyi from the Institute of Zoology of the Chinese Academy of Sciences has characterized the diversity of DNA transposons and expanded the genome engineering toolbox.

7 Jun 2024

Asimov Launches LV Edge Packaging System to Optimize Lentivirus Production

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced the launch of their LV Edge Packaging System, which improves the cost efficiency and reduces the supply chain risk of lentiviral production.

30 Jan 2024

Brunel University London Secures Japanese Patent for Gene Therapy Vector Safety Test

Gene therapy is a rapidly growing area of medical science. But there is little in the way of safety testing the vectors used to deliver gene therapy.

23 Nov 2023

Gaining insights into human disease biology through CRISPR platforms

In this interview, we speak with Laralynne Przybyla about how she is utilizing CRISPR platforms to understand human disease biology in greater detail.

From Society for Laboratory Automation and Screening (SLAS) 7 Feb 2023

Astrea Bioseparations introduces Nereus LentiHERO, a fit-for-purpose solution for lentiviral vector purification

Astrea Bioseparations (“Astrea Bio”), a leading provider of novel purification and separation tools supporting the development of next-generation therapeutics, has announced today the commercial launch of its Nereus LentiHERO™ lentiviral vector (LVV) purification technology.

29 Sep 2022

VectorBuilder to expand with $500 million ‘Gene Delivery Research and Manufacturing Campus

VectorBuilder Inc. has announced the construction of a new R&D and manufacturing center in Guangzhou, China.

From VectorBuilder 12 Apr 2022

Latest tools for COVID-19 Omicron variant research

AMSBIO has announced new additions to its portfolio of tools for COVID-19 research - two monoclonal antibodies that recognize the Spike RBD (B.1.1.529, Omicron Variant) protein and neutralizes its interaction with ACE2.

From AMS Biotechnology 11 Jan 2022

Custom Biofluid & Tissue Procurement Service

Global provider of human and animal biospecimens - AMSBIO offers a custom procurement service enabling researchers to source specific biofluid and tissue samples which are not already available in their extensive biorepository.

From AMS Biotechnology 1 Dec 2021

Novel Assay Platform for 3D Microfluidic Cancer Research

AMSBIO have supplied custom Chimeric antigen receptor (CAR)-T products to the University of Strathclyde (UoS) in Glasgow, UK, and ScreenIn3D Ltd, allowing them to perform novel immune-oncology assays in 3D microfluidic cancer models.

From AMS Biotechnology 1 Oct 2021

New technique to hunt down mutations that cause cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

11 Aug 2021

AMSBIO's custom lentivectors enable visualization of cell nuclei and F-actin cytoskeleton in organoids

AMSBIO have supplied custom lentivectors to Francesco Pampaloni and his team at the Buchmann Institute for Molecular Life Sciences in Frankfurt, Germany allowing them to visualize cell nuclei and F-actin cytoskeleton in their organoids.

From AMS Biotechnology 1 Jun 2021